相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immunoepigenetics Combination Therapies: An Overview of the Role of HDACs in Cancer Immunotherapy
Debarati Banik et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Mechanisms of hepatocellular carcinoma progression
Olorunseun O. Ogunwobi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Neoadjuvant and adjuvant treatment strategies for hepatocellular carcinoma
Clifford Akateh et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets
Daniel Neureiter et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Context-Dependent Role of NF-κB Signaling in Primary Liver Cancer-from Tumor Development to Therapeutic Implications
Carolin Czauderna et al.
CANCERS (2019)
Effects of Wnt-1 blockade in DEN-induced hepatocellular adenomas of mice
Argyrios Sklavos et al.
ONCOLOGY LETTERS (2018)
Pharmacological or transcriptional inhibition of both HDAC1 and 2 leads to cell cycle blockage and apoptosis via p21Waf1/Cip1 and p19INK4d upregulation in hepatocellular carcinoma
Hengyu Zhou et al.
CELL PROLIFERATION (2018)
Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival
F. Invernizzi et al.
DIGESTIVE AND LIVER DISEASE (2018)
Recent developments of c-Met as a therapeutic target in hepatocellular carcinoma
Mohamed Bouattour et al.
HEPATOLOGY (2018)
Mouse models of hepatocellular carcinoma: an overview and highlights for immunotherapy research
Zachary J. Brown et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2018)
Targeting hepatocarcinogenesis model in C56BL6 mice with pan-aurora kinase inhibitor Danusertib
Paschalis Gavriilidis et al.
JOURNAL OF CANCER (2018)
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
A. Vogel et al.
ANNALS OF ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
PTEN lipid phosphatase inactivation links the hippo and PI3K/Akt pathways to induce gastric tumorigenesis
Wenting Xu et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2018)
Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective
Diamantis Tsilimigras et al.
SURGICAL ONCOLOGY-OXFORD (2018)
The Role of PPAR-δ in Metabolism, Inflammation, and Cancer: Many Characters of a Critical Transcription Factor
Yi Liu et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Dysregulation of Nrf2 in Hepatocellular Carcinoma: Role in Cancer Progression and Chemoresistance
Azhwar Raghunath et al.
CANCERS (2018)
Role of Wnt/β-catenin signaling in hepatocellular carcinoma, pathogenesis, and clinical significance
Ahmed M. Khalaf et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2018)
Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics
Faisal Saeed Khan et al.
HEPATOLOGY INTERNATIONAL (2017)
Histone Deacetylase Inhibitors as Anticancer Drugs
Tomas Eckschlager et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2017)
Histone modifications: A review about the presence of this epigenetic phenomenon in carcinogenesis
Emanuely Silva Chrun et al.
PATHOLOGY RESEARCH AND PRACTICE (2017)
Improved treatment of early small hepatocellular carcinoma using sorafenib in combination with radiofrequency ablation
Quanyou Gong et al.
ONCOLOGY LETTERS (2017)
Prognostic value of c-Met overexpression in hepatocellular carcinoma: a meta-analysis and review
Jung Han Kim et al.
ONCOTARGET (2017)
New Insights into the Epigenetics of Hepatocellular Carcinoma
Braira Wahid et al.
BIOMED RESEARCH INTERNATIONAL (2017)
Romidepsin induces G2/M phase arrest via Erk/cdc25C/cdc2/cyclinB pathway and apoptosis induction through JNK/c-Junicaspase3 pathway in hepatocellular carcinoma cells
Wei-Jian Sun et al.
BIOCHEMICAL PHARMACOLOGY (2017)
Nrf2 signaling pathway: Pivotal roles in inflammation
Syed Minhaj Uddin Ahmed et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
HDAC inhibitors suppress c-Jun/Fra-1-mediated proliferation through transcriptionally downregulating MKK7 and Raf1 in neuroblastoma cells
Weiwen He et al.
ONCOTARGET (2016)
The expression of tumor suppressor gene Cyld is upregulated by histone deacetylace inhibitors in human hepatocellular carcinoma cell lines
Panorea Kotantaki et al.
CELL BIOCHEMISTRY AND FUNCTION (2016)
Interleukin 18 binding protein ameliorates ischemia/reperfusion-induced hepatic injury in mice
Nikolaos Ouzounidis et al.
LIVER TRANSPLANTATION (2016)
Efficacy and safety of transarterial chemoembolization plus sorafenib for early or intermediate stage hepatocellular carcinoma: A systematic review and meta-analysis of randomized controlled trials
Jian Zeng et al.
CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY (2016)
HDACs and HDAC Inhibitors in Cancer Development and Therapy
Yixuan Li et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2016)
Biochemical, biological and structural properties of romidepsin (FK228) and its analogs as novel HDAC/PI3K dual inhibitors
Ken Saijo et al.
CANCER SCIENCE (2015)
Hepatocellular carcinoma: Where there is unmet need
Manojkumar Bupathi et al.
MOLECULAR ONCOLOGY (2015)
Romidepsin for the Treatment of Peripheral T-Cell Lymphoma
Swaminathan P. Iyer et al.
ONCOLOGIST (2015)
Protein kinase CK2α catalytic subunit is overexpressed and serves as an unfavorable prognostic marker in primary hepatocellular carcinoma
Hong-Xia Zhang et al.
ONCOTARGET (2015)
The evolving epidemiology of hepatocellular carcinoma: a global perspective
Michael C. Wallace et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2015)
TOP2A Amplification and Overexpression in Hepatocellular Carcinoma Tissues
Ravat Panvichian et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Molecular signalling in hepatocellular carcinoma: Role of and crosstalk among Wnt/β-catenin, Sonic Hedgehog, Notch and Dickkopf-1
Alexandros Giakoustidis et al.
CANADIAN JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2015)
Functional and genetic deconstruction of the cellular origin in liver cancer
Jens U. Marquardt et al.
NATURE REVIEWS CANCER (2015)
Targeting the mTOR pathway in hepatocellular carcinoma: Current state and future trends
Matthias S. Matter et al.
JOURNAL OF HEPATOLOGY (2014)
Urokinase-Type Plasminogen Activator Deficiency Promotes Neoplasmatogenesis in the Colon of Mice
Elisavet Karamanavi et al.
TRANSLATIONAL ONCOLOGY (2014)
Loss of Histone Deacetylases 1 and 2 in Hepatocytes Impairs Murine Liver Regeneration Through Ki67 Depletion
Jie Xia et al.
HEPATOLOGY (2013)
PPARgamma inhibits hepatocellular carcinoma metastases in vitro and in mice
B. Shen et al.
BRITISH JOURNAL OF CANCER (2012)
HDAC1 Inactivation Induces Mitotic Defect and Caspase-Independent Autophagic Cell Death in Liver Cancer
Hong Jian Xie et al.
PLOS ONE (2012)
Inflammation- and stress-related signaling pathways in hepatocarcinogenesis
Hayato Nakagawa et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2012)
Genetics and epigenetics in the fibrogenic evolution of chronic liver diseases
Vincent Zimmer et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2011)
Novel Mechanism by Which Histone Deacetylase Inhibitors Facilitate Topoisomerase II alpha Degradation in Hepatocellular Carcinoma Cells
Mei-Chuan Chen et al.
HEPATOLOGY (2011)
NF-κB in the liver-linking injury, fibrosis and hepatocellular carcinoma
Tom Luedde et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2011)
Tumor initiation and progression in hepatocellular carcinoma: risk factors, classification, and therapeutic targets
Tamara Severi et al.
ACTA PHARMACOLOGICA SINICA (2010)
Role of PPAR-gamma in inflammation. Prospects for therapeutic intervention by food components
Harry Martin
MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS (2010)
The role of signaling pathways in the development and treatment of hepatocellular carcinoma
S. Whittaker et al.
ONCOGENE (2010)
Reactivation of DNA viruses in association with histone deacetylase inhibitor therapy: a case series report
David Ritchie et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2009)
Hepatocarcinogenesis in mice with a conditional knockout of the hepatocyte growth factor receptor c-Met
Philip Marx-Stoelting et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
TOP2A overexpression in hepatocellular carcinoma correlates with early age onset, shorter patients survival and chemoresistance
Nathalie Wong et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Multistep human hepatocarcinogenesis: correlation of imaging with pathology
Masatoshi Kudo
JOURNAL OF GASTROENTEROLOGY (2009)
Loss of hepatocyte growth factor/c-Met signaling pathway accelerates early stages of N-nitrosodiethylamine-induced hepatocarcinogenesis
Taro Takami et al.
CANCER RESEARCH (2007)
Histone deacetylases and cancer
M. A. Glozak et al.
ONCOGENE (2007)
Histone deacetylase inhibitors suppress the inducibility of nuclear factor-κB by tumor necrosis factor-α receptor-1 down-regulation
Gabriele Imre et al.
CANCER RESEARCH (2006)
IKKβ couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis
S Maeda et al.
CELL (2005)
Application of comparative functional genomics to identify best-fit mouse models to study human cancer
JS Lee et al.
NATURE GENETICS (2004)
Potentiation of tumor necrosis factor-induced NF-κB activation by deacetylase inhibitors is associated with a delayed cytoplasmic reappearance of IκBα
E Adam et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Loss of the cylindromatosis tumour suppressor inhibits apoptosis by activating NF-κB
TR Brummelkamp et al.
NATURE (2003)
The tumour suppressor CYLD negatively regulates NF-κB signalling by deubiquitination
A Kovalenko et al.
NATURE (2003)
CYLD is a deubiquitinating enzyme that negatively regulates NF-κB activation by TNFR family members
E Trompouki et al.
NATURE (2003)
分享论文
